Related Experiment Video
Updated: Mar 8, 2026

Chronic Ovine Model of Right Ventricular Failure and Functional Tricuspid Regurgitation
Published on: March 17, 2023
Fabry Disease Presenting with Hypertrophic Cardiomyopathy and Tricuspid Regurgitation
Sang-Cheol Cho1, Han-Wook Yoo2, Jae Won Lee3
1Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Insights
Fabry disease can be easily missed, even in patients with hypertrophic cardiomyopathy. Early clinical suspicion is crucial for timely diagnosis and management of this genetic disorder.
Area of Science:
- Cardiology
- Medical Genetics
Background:
- A 71-year-old female with a history of nonobstructive hypertrophic cardiomyopathy since 1999 presented with dyspnea and severe leg edema.
- The patient underwent cardiac surgery for symptom management, including tricuspid annuloplasty, Maze operation, and right atrial reduction plasty.
Observation:
- Post-surgery follow-up included screening for Fabry disease via plasma alpha-galactosidase activity.
- Initial screening showed alpha-galactosidase activity near the lower normal limit, prompting further investigation.
Findings:
- Genetic analysis confirmed a heterozygote mutation in the alpha-galactosidase gene (c.901C>T, p.Arg301Ter) at exon 6.
- This genetic finding identified the underlying cause of potential Fabry disease.
Implications:
- This case highlights the potential for Fabry disease to be underdiagnosed, particularly in patients with cardiac conditions.
- Emphasizes the critical role of clinical suspicion in identifying Fabry disease, even with borderline biochemical markers.
- Suggests a need for increased awareness and targeted genetic screening for Fabry disease in at-risk populations.
Abstract:
A 71-year-old female who was diagnosed with nonobstructive hypertrophic cardiomyopathy since 1999 presented with dyspnea and severe edema on both legs. For the management of her symptom, cardiac surgery including tricuspid annuloplasty, Maze operation and right atrial reduction plasty was performed. During follow-up after cardiac surgery, a plasma α-galactosidase activity was checked for the screening of Fabry disease and the result was around lower normal limit. DNA analysis was implemented for confirmation and it revealed a heterozygote α-galactosidase mutation at exon 6 [c.901C>T (p.Arg301Ter)]. This case suggests that Fabry disease might be easily undetected, and clinical suspicion is critical.
More Related Videos
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Mitral Regurgitation I: Introduction
Cardiomyopathy IV: Restrictive Cardiomyopathy

